TYRX commercializes implantable combination drug+device products focused on infection control, primarily the AIGISRx Antibacterial Envelope to reduce surgical-site infections associated with cardiac implantable electronic devices (CIEDs). AIGISRx products contain the antimicrobial agents rifampin and minocycline and have been implanted in over 35,000 patients. Multiple clinical studies and conference presentations cited by the company report large reductions in CIED infection rates (for example, an 87% reduction in a Vanderbilt study, a 95% reduction in an interim CITADEL/CENTURION analysis, and a 70% reduction in a propensity-matched cohort). TYRX recently received Health Canada approval for the next-generation AIGISRx R fully resorbable antibacterial envelope. The company cites economic evidence that hospitals can save over $1,000 per high-risk patient when using AIGISRx; patients with CIED infections cost facilities an average of $72,485 and face substantially higher morbidity and mortality. TYRX has attracted strategic investment from the MemorialCare Innovation Fund as part of efforts to advance its technology and deployment in hospital systems. TYRX, Inc., based in Bethesda, Md., commercializes implantable medical devices designed to reduce surgical-site infections associated with cardiac implantable electronic devices (CIEDs), including pacemakers and implantable defibrillators. The company is described in the article as a leader in the commercialization of these devices. Its core products are implantable solutions intended to lower infection risk at surgical sites for CIED patients. TYRX obtained financing to support ongoing commercialization efforts and to provide working capital. The company secured an $8.5 million senior secured credit facility to refinance existing debt and fund operations. Management stated the loan was structured to match TYRX’s needs and help the company continue efforts to reduce patient risks and improve quality of life. TYRX commercializes implantable combination drug and device products focused on infection control, including the AIGISRx Antibacterial Envelope and AIGISRx Flat Sheet. The products contain antimicrobial agents rifampin and minocycline, which have been shown to reduce infections from organisms representing a majority of device‑related endocarditis cases. The company targets infection reduction for patients receiving pacemakers and defibrillators. TYRX is based in Monmouth Junction, NJ. Its commercial focus is on selling these implantable infection‑control products to the cardiac device market. The article reports a recent financing that supports the company’s ongoing commercialization efforts.

Total raised

$29M

Funding rounds

5

Latest round

Debt Financing

Latest activity

Jan 2013